Carcinoma, Non-Small Cell Lung Clinical Trial
Official title:
Open-Label Single-Arm Phase 2 Study of ALIMTA in Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy
In previous phase 2 studies, pemetrexed has shown antitumor activity in advanced non-small cell lung cancer as a single agent as well as in combination with cisplatin. Since the introduction of vitamin supplementation, pemetrexed has shown good tolerance and high safety. Vitamin supplementation has opened the opportunity to offer patients higher pemetrexed dosing, as has been demonstrated by a recent Phase 1 study. The higher dose with supplementation may increase pemetrexed's efficacy without unduly compromising safety. The present Phase 2 study will use pemetrexed dosing that is tailored to individual patient tolerance, and is an effort to determine the efficacy and safety of this approach in patients with advanced NSCLC who had prior chemotherapy.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04486833 -
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
|
Phase 1/Phase 2 | |
| Terminated |
NCT00321308 -
Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT01441128 -
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05358249 -
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
|
Phase 1/Phase 2 | |
| Terminated |
NCT02961283 -
Study of ASN003 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT00973310 -
Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00385996 -
Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT02775006 -
Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma
|
Phase 3 | |
| Completed |
NCT03232593 -
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
|
||
| Terminated |
NCT02590003 -
Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT01514864 -
Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
|
Phase 2 | |
| Completed |
NCT00070629 -
CPG 7909 Injection in Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT02079636 -
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
|
Phase 1 | |
| Completed |
NCT01079520 -
Endobronchial Ultrasound- Transbronchial Needle Aspiration (EBUS-TBNA) Versus Mediastinoscopy for Mediastinal Lymph Node Staging of Non-small Cell Lung Cancer (NSCLC)
|
N/A | |
| Terminated |
NCT01115803 -
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
|
Phase 1 | |
| Completed |
NCT00861627 -
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
|
Phase 2 | |
| Completed |
NCT00923884 -
Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer
|
||
| Recruiting |
NCT04389632 -
A Study of SGN-B6A in Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03603652 -
NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung
|
N/A | |
| Not yet recruiting |
NCT01131429 -
A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations
|
Phase 2 |